Research programme: KRS inhibitors - Yuhan Corporation

Drug Profile

Research programme: KRS inhibitors - Yuhan Corporation

Alternative Names: YH-Chem3; YH-chem4; YH_chem4

Latest Information Update: 16 Dec 2014

Price : $50

At a glance

  • Originator Yuhan
  • Class Small molecules
  • Mechanism of Action Lysine tRNA ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer metastases

Most Recent Events

  • 16 Dec 2014 Preclinical development is ongoing in South Korea
  • 20 Aug 2012 Preclinical trials in Cancer metastases in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top